OmniAb SPAC Presentation Deck
UNIT ECONOMICS AND PIPELINE DEVELOPMENT
TO DRIVE FUTURE VALUE
Key Value
Drivers
Per program economics
Research fees
Clinical and commercial milestones
Royalties
■
Current Portfolio
NPV per program
Peak sales
■
Average royalty rates
Probability of success
Time to approval
Time to peak sales
(1) 2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics (La Merie Publishing).
+
Expected market growth
Pipeline Development
Portfolio expansion
Investments in go-to-market
initiatives
Risk-sharing with partners
■
$236B in antibody sales by 2025(1)
Up from $184B in 2020(1)
Ab market opportunity
Antigen generation
Screening technologies
☐
Next-generation identification and
optimization
30
OmniAbView entire presentation